businessbriefs
12:25in productionCh. 1 · What it is/ 12:25 · ceiling 15 min
Startups & venture · Product

Moderna

2010

Moderna isn’t an RNA platform company—it’s a pandemic procurement vehicle that hasn’t yet proven its tech works beyond emergency use.

Moderna is a vaccine company built on mRNA technology, validated in crisis, not sustained in market.

Startups & ventureProductVaccinesThe pandemicSupply chainsVaccines across the network →
Chapters & takeaways6
  1. 1:04
    What it is

    Moderna is defined by its focus—not broad biotech, but RNA therapeutics, specifically mRNA vaccines.

  2. 2:22
    What it sells

    It has only three commercial products—all vaccines—and no other revenue streams.

  3. 3:44
    Where the money came from

    Its foundational capability was funded by a $25 million DARPA grant to suppress pandemics in 60 days—not by private R&D spend.

  4. 5:15
    What hasn’t shipped

    It has 44 candidates and 37 in trials—but zero additional approved products beyond its three vaccines.

  5. 6:44
    What didn’t scale

    Its early partnerships and spin-outs—in oncology, infectious disease, and chronic conditions—have not yielded approved treatments.

  6. 8:13
    What worked, once

    Its stated DARPA goal—to suppress a global pandemic within 60 days—was operationally met, but only once, under extraordinary conditions.

Worth your time?

Yes. Study the whole thing.

3.5/ 5
What works
  • rapid-vaccine-deployment
  • government-procurement-leverage
  • mRNA-manufacturing-infrastructure
What does not
  • biotech
  • platform
  • oncology
  • chronic-disease
Study it if
  • investors
  • health-policy-makers
  • regulatory-staff
Skip it if
  • consumers
  • primary-care-clinicians
  • long-term-therapeutics-developers
The written brief1 min read

What the company or idea is

Moderna is a pharmaceutical and biotechnology company founded in 2010 in Cambridge, Massachusetts, focused exclusively on RNA therapeutics—primarily mRNA vaccines.

How it actually makes money

Moderna makes money by selling mRNA vaccines: Spikevax (COVID-19), Mresvia (RSV), and Mflusiva (influenza). It has no other commercial products.

What works

Its mRNA platform delivered three approved vaccines in rapid succession—Spikevax, Mresvia, and Mflusiva—leveraging infrastructure built with a $25 million DARPA grant aimed at pandemic response within 60 days.

What does not

Its 44 candidates—37 in clinical trials—have not yielded new commercial products beyond the three vaccines. Its partnerships with AstraZeneca (2013), Alexion (2014), and ventures Onkaido (2014) and Valera (2015) have not produced approved therapies.

What to take from it

Moderna’s business model depends on government and institutional advance-purchase agreements, not recurring consumer demand or payer reimbursement. Its platform remains unproven outside acute viral prevention.

Is it worth your time

Yes—if you want to understand how a biotech startup built a platform business around a single technology, then monetised it through pandemic-scale procurement, not broad-market adoption.

Same desk · Startups & venture4 of 43
10:40
Amgen1980Amgen’s origin story is unusually concrete: founded in 1980, public by 1983, two gene-cloning projects yielding two FDA-approved drugs by 1991. No vague mission statements — just molecules, milestones, and money raised to get there.
10:34
Enphase Energy2006Enphase Energy is a hardware-first energy technology company that built market position by solving a specific, observable failure in residential solar—central inverter underperformance—then scaling through successive generations of microinverters. Its business model relies entirely on third-party installers and distributors. It has no recurring revenue stream, no customer-facing software layer, and no ownership of energy generation. Its success reflects disciplined component-level innovation—not ecosystem control.
9:24
GenmabJan van de Winkel · 1998Genmab is a platform biotech — not a drug developer — built around two licensed and proprietary antibody generation methods. Its value is in reducing discovery risk and time, not in owning clinical or commercial outcomes.
10:45
VolvoAssar Gabrielsson · 1927Volvo’s origin was not a corporate spin-off or investor-backed startup. It was a personal bet — financed by commissions saved in Paris, structured around a high-risk contract, validated by ten physical prototypes, and launched only after institutional rejection. Its early revenue came from trucks, not cars. Its founding story contradicts the myth of visionary consensus — it was a solo act of leverage, execution, and timing.
Up next in Business

Nasdaq

NASD · 1971 · 10:36

Nasdaq didn’t democratise markets — it privatised the plumbing.

Play nextBack to Startups & venture
10:36